Cellectis SA (FR:ALCLS)
:ALCLS
Want to see FR:ALCLS full AI Analyst Report?
ALCLS Stock Chart & Stats
€3.86
-€0.02(-1.32%)
At close: 4:00 PM EST
€3.86
-€0.02(-1.32%)
Day’s Range― - ―
52-Week Range€1.23 - €4.84
Previous CloseN/A
Volume10.86K
Average Volume (3M)852.48K
Market Cap
€196.87M
Enterprise Value€332.96M
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€108.49M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)€51.93M
Bulls Say, Bears Say
Bulls Say
Proprietary Gene‑editing PlatformCellectis’ proprietary gene‑editing platform and focus on allogeneic (off‑the‑shelf) CAR‑T therapies creates a durable competitive advantage: standardized manufacturing, scalability versus autologous approaches, and stronger partnerability that supports recurring collaboration and licensing revenue long-term.
RMAT Designation For Lasme‑celThe RMAT designation is a structural regulatory benefit that can accelerate development and approval timelines, enabling priority interactions with regulators. This reduces clinical/regulatory risk and can materially shorten time to market and partner monetization for the lasme‑cel program.
High Program Gross MarginsReported high gross margins on recent revenues indicate attractive underlying unit economics for Cellectis’ services and program revenues. If clinical candidates advance, these margins support scalable profitability once commercial volumes or recurring partner payments offset fixed R&D and G&A.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the company must rely on external financing to fund trials and operations. That dependence raises dilution and execution risk, can limit investment flexibility, and constrains the firm’s ability to independently advance multiple programs simultaneously.
Rising Leverage, Shrinking EquityElevated debt relative to a declining equity base reduces financial flexibility and increases refinancing and covenant risk. Higher leverage can raise financing costs and limit non-dilutive funding options, making the company more vulnerable if clinical timelines slip or markets tighten.
Modest, Falling Revenue And Deep LossesRevenue is modest and recently declined while net margins and EBIT remain deeply negative. Reliance on collaboration/licensing inflows rather than product sales means persistent operating losses until candidates reach commercialization, limiting self‑funding and increasing execution and financing risk.
Cellectis SA News
ALCLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €1.23 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €196.87M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is in 48 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -€0.153 earnings per share for the quarter, beating the consensus estimate of -€0.221 by €0.068.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.153 in its last earnings report, beating expectations of -€0.221. Following the earnings report the stock price went up 1.658%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in FR:ALCLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
ALCLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---